Patients should stop taking immunomodulating drugs in 3-6 months before admission (depending on variant of medication)
Collection of stem cells (1-3 days).
To rebuild immune system, we need to collect more than 2 million hematopoietic stem cells per kg of body weight (>2 x 106/kg/b.w. CD34+ HSC).
Stem cells collection (harvesting) takes 5-6 hours.
Autologous stem cell harvesting is performed by Haemonetics MCS+ multicomponent collections system or Spectra Optia Apheresis System.
The main morning infusion of Cyclophosphamide with supportive medicine and hydration (3 L of normal saline) and takes 3 hours.
Second and third infusions (mesna uroprotection, nausea prophylaxis) – in 4 and 8 hours after the first one.
Cyclophosphamide with supportive medicine and Fludarabine for first two days,
and only Fludarabine for the last 3-6 days.
From the first day of chemotherapy we start antiviral, antibacterial and antifungal prophylaxis:
– Levofloxacin 500 mg/d,
– Fluconazole 200 mg/d,
– Aciclovire 1200 mg/d,
– Co-trimoxazole (Bactrim) 960 mg/d on Mon, Wen, Fri
Patient should take all tablets:
Pills for breakfast – patient takes one antacid pill before meals, other pills – after meals.
Pills for lunch – patient takes one pill after meals.
Pills for dinner – patient takes one antacid pill before meals, other pills – after meals.
Patient has additional oral medications on Mon, Wen, Fri:
Co-trimoxasole (2 white big pills –morning, evening).
We give Rituximab 500 mg/m² (1 infusion) after immune system recovery (from D+9 to D+12)
After finishing chemotherapy we provide stem cell reinfusion, it takes less than 3 hours
Isolation period during 14 days to rebuild immune system in the aseptic unit of the hospital.
It may take a few months for your immune system to recover and start a NEW LIFE!
In vast majority of cases we don’t recommend vaccinations
Patient immune system has memory, additional vaccination can cause relapse of autoimmune process.
Monitoring of blood tests:
ADIA envisions a future where AHSCT is a widely accessible and transformative treatment option for MS patients. Through our commitment to collaboration, advocacy, and quality care, we aim to redefine the standard of treatment for MS and contribute to improved outcomes and quality of life for those affected by the disease.
Thank you for your interest in our work at ADIA Med. We are committed to advancing MS research and improving patient outcomes. If you have any questions, need more information about our studies, or are interested in investing, our team is here to assist you. Please reach out using the contact form or through the provided contact details, and we will respond as quickly as possible. We look forward to connecting with you and exploring how we can work together to make a meaningful impact in the field of healthcare.
